|
Azenta, Inc., a leading provider of life sciences solutions worldwide, announced the completion of the previously disclosed sale of its B Medical Systems business to Thelema S.à r.l.
The transaction was originally announced on December 29, 2025 and closed on July 1, 2026 following the satisfaction of all closing conditions. Under the terms of the agreement, Azenta sold B Medical Systems for a fixed purchase price of $63 million in cash, of which $35 million was funded through a short-term secured vendor loan from an Azenta subsidiary to Thelema. Additional details regarding the transaction are available in the company's Current Report on Form 8-K filed with the Securities and Exchange Commission.
"The completion of this transaction advances our strategy to simplify and focus the portfolio on our core life sciences businesses," said John Marotta, president and chief executive officer of Azenta. "With enhanced financial flexibility and a continued focus on our core growth platforms, we are well positioned to drive sustainable growth and long-term value for our shareholders."
Azenta, Inc. is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally.
|